Ten years ago, Genome Technology published a guide to genotyping technologies that includes products — complete with performance and pricing information — from 21 vendors. Michael Boyce-Jacino, who was then chief technology officer at the Princeton, NJ-based Orchid BioSciences, now Orchid Cellmark, said the SNP-technology market was "early in its exploding phase" at the time GT's March 2001 issue went to press. Boyce-Jacino also predicted that many genotyping technology firms would merge. "There's definitely not room for all these companies," he told GT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.